Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders

被引:27
作者
Donatti, Amanda [1 ,2 ]
Canto, Amanda M. [1 ,2 ]
Godoi, Alexandre B. [1 ,2 ]
Rosa, Douglas C. [1 ,2 ]
Lopes-Cendes, Iscia [1 ,2 ]
机构
[1] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Dept Med Genet & Genom Med, 126 Cidade Univ Zeferino Vaz, BR-13083887 Campinas, SP, Brazil
[2] Brazilian Inst Neurosci & Neurotechnol, BR-13083887 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
amyotrophic lateral sclerosis; Alzheimer's disease; epilepsy; multiple sclerosis; Parkinson's disease; stroke; metabolomics; mass spectrometry; magnetic nuclear resonance; AMYOTROPHIC-LATERAL-SCLEROSIS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ACUTE ISCHEMIC-STROKE; AMINO-ACID SIGNATURE; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; MASS-SPECTROMETRY; ALPHA-SYNUCLEIN; METABOLOMIC ANALYSIS;
D O I
10.3390/metabo10100389
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.
引用
收藏
页码:1 / 32
页数:32
相关论文
共 50 条
  • [21] GRANINS AS DISEASE-BIOMARKERS: TRANSLATIONAL POTENTIAL FOR PSYCHIATRIC AND NEUROLOGICAL DISORDERS
    Bartolomucci, A.
    Pasinetti, G. M.
    Salton, S. R. J.
    [J]. NEUROSCIENCE, 2010, 170 (01) : 289 - 297
  • [22] Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
    Sanchez-Barcelo, Emilio J.
    Rueda, Noemi
    Mediavilla, Maria D.
    Martinez-Cue, Carmen
    Reiter, Russel J.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2017, 24 (35) : 3851 - 3878
  • [23] Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders
    Barbieri, Raffaella
    Nizzari, Mario
    Zanardi, Ilaria
    Pusch, Michael
    Gavazzo, Paola
    [J]. LIFE-BASEL, 2023, 13 (05):
  • [24] Bile Acid Signaling in Neurodegenerative and Neurological Disorders
    Grant, Stephanie M.
    DeMorrow, Sharon
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 25
  • [25] Gut microbiota-derived metabolites and their importance in neurological disorders
    Swer, Nicole Mary
    Venkidesh, B. S.
    Murali, Thokur Sreepathy
    Mumbrekar, Kamalesh Dattaram
    [J]. MOLECULAR BIOLOGY REPORTS, 2023, 50 (02) : 1663 - 1675
  • [26] Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders
    Kale, Mayur B.
    Umare, Mohit D.
    Wankhede, Nitu L.
    Dehsmukh, Rohitas
    Abbot, Vikrant
    Anwer, Md. Khalid
    Taksande, Brijesh G.
    Upaganlawar, Aman B.
    Umekar, Milind J.
    Ramniwas, Seema
    Gulati, Monica
    Arora, Rashmi
    Behl, Tapan
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2025, 31 (08) : 630 - 644
  • [27] NSAIDs in the treatment and/or prevention of neurological disorders
    Parto S. Khansari
    Leanne Coyne
    [J]. Inflammopharmacology, 2012, 20 (3) : 159 - 167
  • [28] Genetic variation associated with the occurrence and progression of neurological disorders
    Little, Julian
    Barakat-Haddad, Caroline
    Martino, Rosemary
    Pringsheim, Tamara
    Tremlett, Helen
    McKay, Kyla A.
    van Lieshout, Pascal
    Walsh, Stephanie J.
    Gomes, James
    Krewski, Daniel
    [J]. NEUROTOXICOLOGY, 2017, 61 : 243 - 264
  • [29] Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
    Khurana, Mallika
    Rahman, Syed Obaidur
    Najmi, Abul Kalam
    Pottoo, Faheem Hyder
    Akhtar, Sayeed
    [J]. CURRENT PROTEIN & PEPTIDE SCIENCE, 2020, 21 (12) : 1146 - 1163
  • [30] Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders
    Wiefels, Matthew D.
    Furar, Emily
    Eshraghi, Rebecca S.
    Mittal, Jeenu
    Memis, Idil
    Moosa, Moeed
    Mittal, Rahul
    Eshraghi, Adrien A.
    [J]. CURRENT NEUROPHARMACOLOGY, 2024, 22 (01) : 123 - 139